Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Two legs to stand on

The failure of its daclizumab antibody in ulcerative colitis last week removes a leg from the platform Protein Design Labs Inc. is building in inflammatory bowel disease. With two legs of its IBD platform remaining - Nuvion anti-CD3 antibody and HuZaf fontolizumab, a humanized antibody targeting interferon (IFN) gamma - PDLI says it will stick with the disease area.

However, the failure also means that any upside from the $80 million PDLI paid upfront to reacquire rights to daclizumab

Read the full 795 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE